TIMEPOINT | Study Period | ||||
---|---|---|---|---|---|
Enrollment | Allocation | Post-allocation | |||
Birth to 0 | 0 | Surfactant administration (-10min-+10min) | 72 hours after birth | At 36 weeks PMA or at discharge | |
Enrolment: | |||||
Eligibility screen | X | Â | Â | Â | Â |
Informed consent | X | Â | Â | Â | Â |
Allocation | Â | X | Â | Â | Â |
Intervention | |||||
 LISA |  |  | X | X | X |
 LPPSA |  |  | X | X | X |
Assessments | |||||
Primary outcomes  1.Need for ventilation during the first 72 hours |  |  |  | X |  |
 2. Mortality  3. BPD |  |  |  |  | X |
Secondary outcomes Need for and the duration of MV (days), duration (days) of non-invasive respiratory support, severe co-morbidities, pneumothorax, massive pulmonary hemorrhage within 48 h of surfactant administration, hemodynamically significant patent ductus arteriosus that needs medical or surgical intervention, Duration of hospitalization, Failure rate of LISA or LPPSA | Â | Â | X | X | X |